Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) saw unusually large options trading on Thursday. Investors purchased 1,587 put options on the company. This represents an increase of approximately 807% compared to the average volume of 175 put options.

Ionis Pharmaceuticals (NASDAQ IONS) opened at $52.43 on Friday. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50. Ionis Pharmaceuticals has a 1-year low of $37.26 and a 1-year high of $65.51. The company has a market capitalization of $6,630.00, a price-to-earnings ratio of 343.73 and a beta of 2.85.

A number of equities research analysts recently weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a research note on Tuesday, October 17th. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $68.00 price target on the stock in a research note on Tuesday, October 17th. Stifel Nicolaus restated a “hold” rating and issued a $50.00 price target on shares of Ionis Pharmaceuticals in a research note on Friday, October 13th. Goldman Sachs Group restated a “sell” rating and issued a $30.00 price target on shares of Ionis Pharmaceuticals in a research note on Friday, October 6th. Finally, Barclays assumed coverage on Ionis Pharmaceuticals in a research note on Wednesday, September 6th. They issued an “equal weight” rating and a $55.00 price target on the stock. Three analysts have rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $50.31.

In other news, CEO Stanley T. Crooke sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $52.00, for a total transaction of $780,000.00. Following the sale, the chief executive officer now owns 43,014 shares in the company, valued at approximately $2,236,728. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Patrick R. O’neil sold 1,000 shares of the stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $55.00, for a total value of $55,000.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 123,886 shares of company stock worth $7,098,315. Company insiders own 2.13% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. AXA acquired a new position in Ionis Pharmaceuticals in the 3rd quarter valued at $5,202,000. Steward Partners Investment Advisory LLC acquired a new position in Ionis Pharmaceuticals in the 3rd quarter valued at $100,000. GSA Capital Partners LLP grew its holdings in Ionis Pharmaceuticals by 10.9% in the 3rd quarter. GSA Capital Partners LLP now owns 23,893 shares of the company’s stock valued at $1,211,000 after buying an additional 2,348 shares in the last quarter. Iguana Healthcare Management LLC acquired a new position in Ionis Pharmaceuticals in the 3rd quarter valued at $761,000. Finally, Parallel Advisors LLC grew its holdings in Ionis Pharmaceuticals by 60.3% in the 3rd quarter. Parallel Advisors LLC now owns 3,323 shares of the company’s stock valued at $182,000 after buying an additional 1,250 shares in the last quarter. 91.57% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Traders Buy Large Volume of Put Options on Ionis Pharmaceuticals (IONS)” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/traders-buy-large-volume-of-put-options-on-ionis-pharmaceuticals-ions/1768901.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.